A federal appeals court will hear arguments about whether companies can patent genes on July 20. The  American Civil Liberties Union has challenged Myriad Genetics’ patents on the BRCA 1 and BRCA2 genes, which affect the risk of breast and ovarian cancer. The Supreme Court sent the... [More]

Petitioners challenging the patent eligibility of isolated DNA filed a reply brief Jan. 20, rejecting the respondent patent owner's call for the U.S. Supreme Court to deny review of the case for lack of standing (Association for Molecular Pathology v. Myriad Genetics Inc., U.S., No. 11-725, re... [More]

Myriad Genetics retained its monopoly on a lucrative genetic test for breast cancer risk when a federal appeals court recently upheld the company’s patents on two human genes — and the validity of gene patents in general. But it is only a matter of time before the company’s... [More]